PUT/VERTEX PHARMACEUTICALS/400/0.1/16.01.26 | Real-time BOERSE MUENCHEN 17:26:09 03/07/2024 BST | ||
| 2.6 EUR | -1.89% |
|
| Current month | +2.71% | ||
| 1 month | -16.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 2.6 | -1.89% |
| 02/07/24 | 2.65 | -0.38% |
| 01/07/24 | 2.66 | +3.10% |
| 28/06/24 | 2.58 | +1.18% |
| 27/06/24 | 2.55 | -5.56% |
Real-time BOERSE MUENCHEN
Last update July 03, 2024 at 05:26 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG24CJ |
| ISIN | DE000GG24CJ6 |
| Date issued | 23/01/2024 |
| Strike | 400 $ |
| Maturity | 16/01/2026 (562 Days) |
| Parity | 10 : 1 |
| Emission price | 3.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.15 € |
|---|---|
| Lowest since issue | 2.29 € |
| Spread | 0.18 € |
| Spread % | 6.82% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
468.3
USD
Spread / Average Target
-1.16%
- Stock Market
- Warrants
- Warrant
